Published in S Afr Med J on April 01, 1998
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.50
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08
Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA (1997) 4.09
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet (2001) 3.71
Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol (1995) 3.51
Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ (1997) 3.51
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05
Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet (1999) 2.97
Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet (1988) 2.84
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81
Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci (1988) 2.73
Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group . Lancet (1999) 2.54
Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. Eur J Clin Microbiol Infect Dis (1996) 2.43
A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med (1998) 2.42
Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med (2000) 2.31
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27
Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ (1999) 2.18
Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med (2003) 2.17
Malaria chemoprophylaxis: why mefloquine? Lancet (1990) 2.13
Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci (1993) 2.08
Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med (1985) 2.04
The Thucydides syndrome. A new hypothesis for the cause of the plague of Athens. N Engl J Med (1985) 2.04
The effect of do-not-resuscitate orders on length of stay. Cleve Clin J Med (1992) 2.03
Recognition for faces of own and other race. J Pers Soc Psychol (1969) 2.01
MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety. J Neurol Neurosurg Psychiatry (2010) 1.84
Paternal age effect in Down's syndrome. Ann Hum Genet (1977) 1.84
Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci U S A (1994) 1.79
The Onchocerciasis Elimination Program for the Americas: a history of partnership. Rev Panam Salud Publica (1998) 1.79
Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components. Immunol Rev (1989) 1.73
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Incidence study of Down's syndrome in Copenhagen, 1960-1971; with chromosome investigation. Ann Hum Genet (1976) 1.72
Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess (2005) 1.71
Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol (1991) 1.70
Cholesterol and total mortality: need for larger trials. BMJ (1992) 1.57
The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis. Bull World Health Organ (1999) 1.56
The trials of Dr. Bernard Fisher: a European perspective on an American episode. Control Clin Trials (1997) 1.49
The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Arch Dis Child (2006) 1.49
Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord (2001) 1.49
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens (2001) 1.49
Unrecognized coccidioidomycosis complicating Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus and treated with corticosteroids. A report of two cases. Arch Intern Med (1993) 1.48
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med (2014) 1.48
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Dynamic sonography with provocation of pain for diagnosis of symptomatic mobile kidneys. Eur J Surg (2001) 1.46
A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J (2005) 1.46
Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. J Clin Microbiol (2001) 1.44
Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial. J Bone Joint Surg Br (1994) 1.44
Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology (2010) 1.44
Quantitative bacterial examination of domestic water supplies in the Lesotho Highlands: water quality, sanitation, and village health. Bull World Health Organ (1999) 1.43
Characterization of the cross-reacting determinant (CRD) of the glycosyl-phosphatidylinositol membrane anchor of Trypanosoma brucei variant surface glycoprotein. Eur J Biochem (1988) 1.43
Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies. Clin Diagn Lab Immunol (1996) 1.41
Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J (2002) 1.41
Maternal brain death and prolonged fetal survival. Obstet Gynecol (1989) 1.39
Bilateral papillitis in ocular toxoplasmosis. Eye (Lond) (2009) 1.39
Randomization. Nature (1994) 1.38
Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem (2001) 1.38
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J (1994) 1.38
Usefulness of Toxoplasma gondii-specific recombinant antigens in serodiagnosis of human toxoplasmosis. J Clin Microbiol (2004) 1.37
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation (1989) 1.36
Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma. J Clin Invest (1984) 1.36
A systematic review of cancer waiting time audits. Qual Saf Health Care (2005) 1.35
Gender differences in mood and cardiovascular responses to socially stressful stimuli. Ethn Dis (1996) 1.35
Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol (1998) 1.33
Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA (1988) 1.29
Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am J Trop Med Hyg (1992) 1.29
Recombinant Plasmodium falciparum glutamate rich protein; purification and use in enzyme-linked immunosorbent assay. Am J Trop Med Hyg (1991) 1.28
Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med (1987) 1.28
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
Multicenter evaluation of strategies for serodiagnosis of primary infection with Toxoplasma gondii. Eur J Clin Microbiol Infect Dis (2001) 1.26